A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder

Aim To assess the efficacy and safety of imidafenacin compared with propiverine for treatment of overactive bladder (OAB) in Korean patients. Materials and methods Patients with OAB symptoms were randomised to double-blind treatment with 0.1 mg of imidafenacin twice daily (group A) or propiverine 20 mg once daily (group B) for 12-week regimen, and assessed for efficacy and safety. The primary efficacy outcome was per cent change of weekly urgency urinary incontinence (UUI) episodes at week 12. The secondary efficacy outcomes were changes in the micturitions per day, urine volume voided per micturition, urgency episodes per day, complete disappearance of incontinence episodes and severity of urgency from baseline to week 12. Quality of life and safety profiles were also compared. Results Of 162 patients randomised, 140 completed the study protocol. The per cent change of weekly UUI episodes at week 12 was −69.1% in group A and −70.4% in group B (both p